TLDR
- DataMeds AI and Tollo Health launched the Health Lives Here mobile app for GLP-1 medication users.
- The app is marketed through a partnership with NFL Alumni Health.
- A new pharmacy network is starting with Moose Pharmacy of Concord in North Carolina.
- MEDS stock fell 11% on the day of the announcement.
- The company plans to expand into Long COVID and cancer patient populations later this year and next.
DataMeds AI (MEDS) stock dropped 11% on Monday as the company rolled out a new health app. Shares fell to $3.11 during the session.
The Tampa-based company teamed up with Tollo Health to launch the Health Lives Here mobile application. The app initially targets users of GLP-1 receptor agonist medications.
DataMeds AI is marketing the app through a partnership with NFL Alumni Health. That’s the health-focused arm of the National Football League Alumni Association.
Pharmacy Network Rolls Out Alongside App
The launch comes with a new Health Lives Here healthcare network. It starts with independent pharmacies chosen from the Corexa Health subsidiary’s existing pharmacy list.
Moose Pharmacy of Concord in North Carolina is the first pharmacy in the network. More locations are expected to join over time.
The app connects users with licensed physicians for telemedicine evaluations. Patients can get assessed for GLP-1 therapies right from their phone.
Corexa’s pharmacy arm offers cash-pay options for branded GLP-1 medications. Home delivery is included, or users can send prescriptions to a local pharmacy of their choice.
The app also sells Tollo Health’s Forzet, a medical food product. It’s designed to help manage muscle loss that can come with weight loss treatments, and it doesn’t need a prescription.
Wearables and AI Features Built Into the App
Health Lives Here pulls in data from popular wearables. That includes Apple Watch, Samsung Galaxy Watch, WHOOP and Oura Ring.
The app comes with an AI health coach and activity logging tools. There’s also an AI chatbot built to spot crisis language and point users toward emergency help.
DataMeds AI isn’t stopping at GLP-1 users. The company plans to expand the app to Long COVID patients in the fourth quarter of 2026.
Cancer patients are next on the list after that. No firm timeline was given for that expansion.
Diagnostic lab services are also in the pipeline. These would come through the company’s acquisition of Helomics Corporation, letting customers order direct-to-consumer lab tests where local law allows it.
Looking further out, DataMeds AI wants to add digital twin capabilities. A broader provider network is planned for 2027.
Gerald Commissiong is Interim Co-CEO of DataMeds AI. He also serves as CEO of Tollo Health, the app’s launch partner.
The stock’s double-digit drop stands out given the product news. Investors may be weighing execution risk against the early stage of the rollout.
For now, the Health Lives Here app is live with one pharmacy partner on board. The company has laid out a multi-year roadmap but has not shared user or revenue figures tied to the launch.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Be the first to comment